RU2012127383A - Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке - Google Patents
Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке Download PDFInfo
- Publication number
- RU2012127383A RU2012127383A RU2012127383/10A RU2012127383A RU2012127383A RU 2012127383 A RU2012127383 A RU 2012127383A RU 2012127383/10 A RU2012127383/10 A RU 2012127383/10A RU 2012127383 A RU2012127383 A RU 2012127383A RU 2012127383 A RU2012127383 A RU 2012127383A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- modified
- amino acid
- heterologous
- linked glycosylation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 40
- 210000002966 serum Anatomy 0.000 title claims abstract 12
- 102000004169 proteins and genes Human genes 0.000 title claims 4
- 108090000623 proteins and genes Proteins 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims abstract 37
- 230000004988 N-glycosylation Effects 0.000 claims abstract 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract 9
- 108020004707 nucleic acids Proteins 0.000 claims abstract 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 9
- 108020001756 ligand binding domains Proteins 0.000 claims abstract 7
- 239000003446 ligand Substances 0.000 claims abstract 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000027455 binding Effects 0.000 claims abstract 4
- 238000004113 cell culture Methods 0.000 claims abstract 4
- 241000282693 Cercopithecidae Species 0.000 claims abstract 3
- 238000004458 analytical method Methods 0.000 claims abstract 3
- 230000004071 biological effect Effects 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 108020001507 fusion proteins Proteins 0.000 claims 33
- 102000037865 fusion proteins Human genes 0.000 claims 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 230000013595 glycosylation Effects 0.000 claims 15
- 238000006206 glycosylation reaction Methods 0.000 claims 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 10
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 239000004161 brilliant blue FCF Substances 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000027257 transmembrane receptors Human genes 0.000 claims 1
- 108091008578 transmembrane receptors Proteins 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26609509P | 2009-12-02 | 2009-12-02 | |
| US61/266,095 | 2009-12-02 | ||
| US32758210P | 2010-04-23 | 2010-04-23 | |
| US61/327,582 | 2010-04-23 | ||
| PCT/US2010/058765 WO2011068993A1 (en) | 2009-12-02 | 2010-12-02 | Compositions and methods for increasing serum half-life of fc fusion proteins. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012127383A true RU2012127383A (ru) | 2014-01-10 |
Family
ID=44115295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012127383/10A RU2012127383A (ru) | 2009-12-02 | 2010-12-02 | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8722615B2 (enExample) |
| EP (1) | EP2507267B1 (enExample) |
| JP (1) | JP2013512674A (enExample) |
| KR (1) | KR20140015152A (enExample) |
| CN (1) | CN102770458A (enExample) |
| AU (1) | AU2010325943A1 (enExample) |
| BR (1) | BR112012013330A2 (enExample) |
| CA (1) | CA2782320A1 (enExample) |
| IN (1) | IN2012DN05169A (enExample) |
| RU (1) | RU2012127383A (enExample) |
| WO (1) | WO2011068993A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| WO2011068993A1 (en) | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| CN104662039B (zh) * | 2012-07-18 | 2019-10-08 | 阿珀吉尼科斯股份公司 | 缩短的CD95-Fc变体 |
| WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| EP2969009B1 (en) * | 2013-03-15 | 2018-11-28 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
| GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| RS60156B1 (sr) | 2014-02-02 | 2020-05-29 | Medimmune Ltd | Himerni protein sačinjen od ngf antagonist domena i tnfa antagonist domena |
| EP3122371A4 (en) | 2014-03-28 | 2017-09-06 | New York University | Fgf23 fusion proteins |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| WO2016069889A1 (en) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| US9975934B2 (en) | 2015-03-26 | 2018-05-22 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| WO2016197071A1 (en) | 2015-06-05 | 2016-12-08 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
| WO2017023855A1 (en) * | 2015-07-31 | 2017-02-09 | The General Hospital Corporation | Protein prostheses for mitochondrial diseases or conditions |
| CA3004830A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| HRP20240603T1 (hr) | 2016-07-01 | 2024-07-19 | Resolve Therapeutics, Llc | Optimizirane fuzije binukleaze i postupci njihove upotrebe |
| CA3073537A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
| WO2020050626A1 (ko) * | 2018-09-05 | 2020-03-12 | 주식회사 엘지화학 | O-글리코실화 가능한 폴리펩타이드 영역을 포함하는 융합 폴리펩타이드 |
| CN113597319A (zh) | 2019-01-04 | 2021-11-02 | 分解治疗有限责任公司 | 用核酸酶融合蛋白治疗干燥症 |
| CA3165342A1 (en) | 2020-06-29 | 2022-01-06 | James Arthur Posada | Treatment of sjogren's syndrome with nuclease fusion proteins |
| WO2025147696A1 (en) | 2024-01-05 | 2025-07-10 | Resolve Therapeutics, Llc | Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
| ATE236249T1 (de) * | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| GB9022648D0 (en) * | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
| JP3122139B2 (ja) | 1991-10-15 | 2001-01-09 | マラーキー，ミッシェル，エフ． | 後期段階炎症反応の治療用組成物 |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| US5869337A (en) * | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) * | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| WO1995026985A1 (en) * | 1994-04-05 | 1995-10-12 | Board Of Regents, The University Of Texas System | Modified receptors that continuously signal |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US7094564B1 (en) * | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
| US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
| US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US5570401A (en) * | 1995-09-22 | 1996-10-29 | General Electric Company | BWR containment configuration having partitioned wetwell airspace |
| DE69724451T2 (de) * | 1996-12-06 | 2004-03-18 | Amgen Inc., Thousand Oaks | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6265535B1 (en) * | 1997-05-30 | 2001-07-24 | The Trustees Of The University Of Pennsylvania | Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses |
| AU9222698A (en) | 1997-09-05 | 1999-03-22 | Millennium Biotherapeutics, Inc. | Novel molecules of the tnfr-ligand-related protein family and uses thereof |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| US6419919B2 (en) * | 1997-11-07 | 2002-07-16 | John D. Mountz | Method for the augmentation of gene expression |
| US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| JP2002503464A (ja) | 1998-02-17 | 2002-02-05 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒト短鎖ｔｎｆ受容体ファミリタンパク質 |
| JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
| ES2324846T3 (es) * | 1998-03-04 | 2009-08-17 | Bristol-Myers Squibb Company | Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6693181B2 (en) * | 1998-04-16 | 2004-02-17 | Genentech, Inc. | Protein secretion |
| US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| SE9803710L (sv) * | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Användning av vissa substanser för behandling av nervrotsskador |
| JP4598954B2 (ja) * | 1998-10-20 | 2010-12-15 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） | 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用 |
| AU764479B2 (en) * | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| US7294481B1 (en) * | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| CN1763097B (zh) | 1999-01-15 | 2011-04-13 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| WO2000050436A1 (en) | 1999-02-23 | 2000-08-31 | Genaissance Pharmaceuticals, Inc. | Receptor isogenes: polymorphisms in the tissue necrosis factor receptor |
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6498165B1 (en) * | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| ES2274378T3 (es) * | 1999-08-10 | 2007-05-16 | Glaxo Group Limited | Ligando del receptor ep4 y uso contra dolor neuropatico, cancer de colon,hiv y migraña. |
| EP1210411B1 (en) * | 1999-08-25 | 2006-10-18 | Immunex Corporation | Compositions and methods for improved cell culture |
| GB9927681D0 (en) | 1999-11-23 | 2000-01-19 | Glaxo Group Ltd | Protein |
| ES2269366T3 (es) * | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
| CA2400214A1 (en) | 2000-02-11 | 2001-11-15 | Amgen Inc. | Fusion receptor from tnf family |
| EP1259616A2 (en) * | 2000-03-02 | 2002-11-27 | Xencor | Tnf-alpha variants for the treatment of tnf-alpha related disorders |
| DE60120372T2 (de) * | 2000-03-24 | 2007-07-05 | Genentech Inc., San Francisco | Verwendung von insulin zur behandlung von knorpelkrankheiten |
| US6800300B1 (en) * | 2000-03-31 | 2004-10-05 | Vasogen Ireland Limited | Method for treating autoimmune and alloimmune diseases |
| ES2330330T3 (es) | 2000-06-28 | 2009-12-09 | Glycofi, Inc. | Procedimiento de produccion de glucoproteinas modificadas. |
| CA2421588C (en) | 2000-09-05 | 2010-01-26 | Amgen Inc. | Tnf receptor-like molecules and uses thereof |
| US6610750B1 (en) * | 2000-09-15 | 2003-08-26 | Laboratoires Negma | Treatment of osteoarthritis |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US20020150582A1 (en) * | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
| HUP0303246A2 (hu) * | 2001-02-23 | 2003-12-29 | Immunex Corporation | Aktív fehérjék fokozott kinyerése |
| US6972327B1 (en) * | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| HK1080090B (zh) * | 2001-10-10 | 2012-12-14 | 诺和诺德公司 | 肽的重构和糖缀合的方法 |
| KR20050042062A (ko) * | 2001-11-07 | 2005-05-04 | 에프. 호프만-라 로슈 아게 | 아미노피리미딘 및 피리딘 |
| CA2469815C (en) * | 2001-12-21 | 2011-05-03 | Immunex Corporation | Methods for purifying protein |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| MXPA04008215A (es) * | 2002-02-27 | 2004-11-26 | Immunex Corp | Formulacion polipeptidica. |
| DE10209821A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| CA2480121C (en) * | 2002-03-27 | 2012-02-28 | Immunex Corporation | Methods for increasing polypeptide production |
| US6974681B1 (en) * | 2002-08-23 | 2005-12-13 | Immunex Corporation | Cell culture performance with vanadate |
| US7067279B1 (en) * | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
| US6924124B1 (en) * | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| WO2004091499A2 (en) | 2003-04-09 | 2004-10-28 | Neose Technologies, Inc. | Intracellular formation of peptide conjugates |
| US7892563B2 (en) * | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| WO2004113387A2 (en) | 2003-06-24 | 2004-12-29 | Merck Patent Gmbh | Tumour necrosis factor receptor molecules with reduced immunogenicity |
| SG145712A1 (en) * | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| JP2007501812A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
| US7268116B2 (en) * | 2003-10-02 | 2007-09-11 | Genhunter Corp. | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| KR20050082389A (ko) | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
| US7507745B2 (en) * | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| JP4940136B2 (ja) | 2004-06-28 | 2012-05-30 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | キメラタンパク質およびその使用 |
| US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| WO2006079176A1 (en) | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| EP2298295B1 (en) | 2005-01-31 | 2013-08-28 | Cephalon, Inc. | Tumor necrosis factor inhibitors |
| US8124732B2 (en) | 2005-06-24 | 2012-02-28 | Synageva Biopharma Corp. | Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken |
| ES2390354T3 (es) * | 2005-07-22 | 2012-11-12 | Amgen, Inc | Liofilizados de proteínas concentrados, procedimientos y usos |
| CN1954882A (zh) | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
| US7626895B2 (en) * | 2005-12-01 | 2009-12-01 | International Business Machines Corporation | Removable media battery pack for powering a media accessor of an automated data-storage library |
| AU2007309650A1 (en) | 2006-02-08 | 2008-05-02 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| EP2059527B1 (en) | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| IL182956A0 (en) | 2007-05-03 | 2008-01-20 | Yeda Res & Dev | Glycan modified soluble receptors and binding proteins and their use |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| CN101778937A (zh) | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| EP3150218B1 (en) * | 2007-09-21 | 2021-09-08 | The Regents Of The University Of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
| DK2340031T3 (da) * | 2008-08-14 | 2019-07-15 | Acceleron Pharma Inc | Gdf-fanger til anvendelse ved behandling af anæmi |
| EP2440576A4 (en) * | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| WO2011068993A1 (en) | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
-
2010
- 2010-12-02 WO PCT/US2010/058765 patent/WO2011068993A1/en not_active Ceased
- 2010-12-02 JP JP2012542194A patent/JP2013512674A/ja not_active Withdrawn
- 2010-12-02 CN CN2010800629282A patent/CN102770458A/zh active Pending
- 2010-12-02 KR KR1020127017129A patent/KR20140015152A/ko not_active Withdrawn
- 2010-12-02 EP EP10835138.8A patent/EP2507267B1/en active Active
- 2010-12-02 US US12/959,220 patent/US8722615B2/en active Active
- 2010-12-02 AU AU2010325943A patent/AU2010325943A1/en not_active Abandoned
- 2010-12-02 CA CA2782320A patent/CA2782320A1/en not_active Abandoned
- 2010-12-02 RU RU2012127383/10A patent/RU2012127383A/ru not_active Application Discontinuation
- 2010-12-02 IN IN5169DEN2012 patent/IN2012DN05169A/en unknown
- 2010-12-02 BR BR112012013330A patent/BR112012013330A2/pt not_active IP Right Cessation
-
2014
- 2014-04-24 US US14/261,212 patent/US20150010555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011068993A1 (en) | 2011-06-09 |
| US20110171218A1 (en) | 2011-07-14 |
| KR20140015152A (ko) | 2014-02-06 |
| CN102770458A (zh) | 2012-11-07 |
| US8722615B2 (en) | 2014-05-13 |
| EP2507267A4 (en) | 2013-05-29 |
| IN2012DN05169A (enExample) | 2015-10-23 |
| AU2010325943A1 (en) | 2012-06-21 |
| US20150010555A1 (en) | 2015-01-08 |
| EP2507267A1 (en) | 2012-10-10 |
| CA2782320A1 (en) | 2011-06-09 |
| BR112012013330A2 (pt) | 2017-03-28 |
| EP2507267B1 (en) | 2016-09-14 |
| JP2013512674A (ja) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012127383A (ru) | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке | |
| JP7560507B2 (ja) | ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法 | |
| US9212231B2 (en) | TRAIL R2-specific multimeric scaffolds | |
| CA2871145A1 (en) | Fibroblast growth factor 21 proteins | |
| AU2012228990A1 (en) | Potent and selective inhibitors of Nav1.3 and Nav1.7 | |
| CN106457070A (zh) | 基于IL‑15/IL‑15Rα的缀合物的纯化方法 | |
| CN102875683B (zh) | 长效重组人生长激素的Fc融合蛋白 | |
| WO2021247675A9 (en) | Coronavirus-binding agents and uses thereof | |
| JP7440516B2 (ja) | 切断多価多量体 | |
| JP5100662B2 (ja) | Ｂｍｐ−７変異体組成物、方法および使用 | |
| WO2020219896A1 (en) | Cd80 variant proteins and uses thereof | |
| CN115073607A (zh) | Tnfr2与baff受体的融合蛋白 | |
| HK40090436A (zh) | Cd40l-特异性tn3-衍生的支架及其使用方法 | |
| HK1180695B (en) | Trail r2-specific multimeric scaffolds | |
| HK1180695A (en) | Trail r2-specific multimeric scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20131203 |